Call Us      +44 (0)20 70961222

Oncology

JOIN OUR USA EAST COAST 2018 STRATEGY MEETING


12th November 2018, The Westin Boston Waterfront

OUR UNIQUE FORMAT

The Oncology Roundtable Discussions Strategy Meeting are for qualified end-users. These include Senior Executives of Oncology/Immuno-Oncology (from medium to large Pharma, Biopharma and Biotech players) in global positions spanning early to phase IV, as well as thought leaders from Academia and regulatory authorities.

Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Oncology R&D,Translational Research/Development/Medicine, Clinical Research/Development, Immuno-Oncology, Medical Affairs Oncology,Clinical Pharmacology,Oncology Clinical Biostatistics and Programming, Oncology Clinical Genomics and Computational Biology, Oncology R&D Innovation, Oncology R&D Strategy, Oncology Portfolio/Project Management.

FACILITATORS
Jeffrey Humphrey

Jeffrey Humphrey

President and Chief Medical Officer

Kyowa Kirin Pharmaceutical Development, Inc.

ramon

Ramon Monhalal

Chief Medical Officer and Executive Vice President

BeyondSpring Pharmaceuticals

alok

Alok Bhushan

Chair of the Department of Pharmaceutical Sciences

Philadelphia University + Thomas Jefferson University

john Quackenbush-1

John Quackenbush

Professor of Computational Biology and Bioinformatics

Harvard T.H. Chan School of Public Health

ADVISORY BOARD
Jeffrey-Humphrey-1-270×260

Jeffrey Humphrey

President & Chief Medical Officer

Kwoya Kirin Pharmaceutical Development Inc.

Rakesh-Dixit1-270×260

Rakesh Dixit

Vice President

Research & Development, MedImmune

WHAT TO EXPECT
roundtable
Interactive Roundtable Discussions

Attendees can proactively share and ask questions to their peers about the success of their work in an informal setting.

one to one copy
Director level one-to-one meetings

We provide opportunities to engage with one another in our strategy meeting in a series of pre-arranged business meetings by interacting face to face.

agenda
Tailor-fit and Personalized Agenda

Being able to experience different sessions is what makes our event unique that’s why our attendees can personalize and select sessions they want to participate in.

netwkorking copy
Networking Opportunities

Several networking opportunities are in store for attendees to connect and build new relationships with their peers through luncheons, cocktails and informal introductions.

Thank you for reaching Proventa International

One of our executives will contact you within 24 hours

ONCOLOGY

STRATEGY MEETING USA WEST COAST 2018








***The information you provided in this website is confidential and the company will strictly forbidden to share any part of these information with any third party without a written consent of the sender.

BECOME SPONSOR

If you are an exciting start-up trying to get your innovation in front global heads from the leading Pharmaceutical companies,
or a mature market-leading conglomerate with legacy solutions trying to stay one step ahead of the competition – we are here to help!
WHAT PEOPLE SAY

Oncology Strategy Meeting USA East Coast 2016

Samuel T. Labrie, VP Corporate Development, Myriad RBM

Kam Dhaliwal, SVP Services & Alliances, Horizon Discovery

Matt Hersch, Clinical Operations Manager, GW Pharmaceuticals

Rainer Metzger,  VP Global Business Development Pharma, Qiagen

Dilsaid Babayigit, Founder & CEO, Ageneo

John Apathy, Vice President, R&D informatics, Celgene

Lars Branden, Senor Director,Informatics R&D Division, Retro Screen Virology Ltd.

Dominic Clark , Industry Programme Manager, EMBL-EBI

Yike Guo, Director Data Science Institude, Imperial College London

John Wise, Executive Director, Pistoia Alliance

Abel Ureta-Vida, CEO, Eagle Genomics

Alexander Scheer, Deputy Head of Research, Pierre Fabre

Jerome Wojcik , CEO, Quartz Bio

Oleksandr Otava, Head Of Scientific IT, Affiris AG

Sowmyanarayan Srinivasan, Director R&D Practise, Global Delivery Leader Discovery

Yaron Turpaz

Chief Information Officer

Its nice because they basically allowed people to engaged to discussions and questions. Academic and industry is very nice and informative

Ivan John Clement

Data Scientist - R&D

Its good because you really get the people to talk. They are willing to share their knowledge, the juniors are very eager to learn.

Raghuraman Gopal

Manager Quality Assurance

The format is the beginning of breakthrough and integration, the level of delegates is very good and excellent, they learn a lot.

Dadabhai Singh

Founder & President

The kind of interaction is very interactive

Steve Rozen

Director & Professor

Because of diversity we really districts the points and all. People are very diversity and thoughtful in a round table.

Images coming soon

VENUE

THE WESTIN
BOSTON WATERFRONT


Address

425 Summer St, Boston, MA 02210, USA


Phone

+1 617-532-4600

OUR MEDIA PARTNERS




Jeffrey-Humphrey-1-270×260 (1)

Jeffrey Humphrey

President & Chief Medical Officer

Kwoya Kirin Pharmaceutical Development Inc.

Stefan-Scherer

Stefan Scherer

Vice President, Head Academic Medical Innovation

Novartis

Eric-Kowack

Eric Kowack

Vice President, Team Leadership & Head of Precision Medicine

Ignyta

Donna-Jarlenski

Donna Jarlenski

Vice President, Clinical Operations

Mersana Therapeutics

Judy Chou

Senior Vice President and Head of Product Supply Biotech, Bayer Pharmaceuticals

With more than 20 years of industry experience in biomanufacturing and drug , Dr. Judy Chou currently heads the global Pharmaceutical Product SupplyBiotech organization overseeing the manufacturing and distribution of Bayer’s $3 billion biotechnology product portfolio. In addition, she serves as the site head for Bayer’s facility in Berkeley, CA, USA.

Before Bayer, she held the role of Vice President of Pharmaceutical/Technical Operations at Pfizer, Inc., formerly Medivation, where she led the Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D at Tanvex Biopharma, Inc., where Dr. Chou led the of rich pipeline projects and provided leadership in R&D, manufacturing, preclinical and clinical functions to enable the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in protein therapeutic and multiple filings of BLAs and INDs of novel products. She is recognized for her work at Genentech, Wyeth Biopharma/Pfizer and Abbott Bioresearch/AbbVie, and has contributed to the of breakthrough technologies in analytical characterization and the accelerated process and formulation .

Before joining the industry, Dr. Chou was also a research faculty member at Harvard University Medical School, focused on cell biology and neuroscience research. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany.

Suhasini-Iyer-270×260 (1)

Suhasini Iyer

Senior Vice President, Development Sciences & Regulatory Affairs, Teneobio, Inc

Dr. Iyer has over 20 years of experience in the biotech industry that spans drug discovery, translational research, regulatory interactions and clinical . Prior to joining Teneobio in April 2017, Dr. Iyer was at Abbvie as Global Project Leader in Oncology Clinical Development where she led programs in early . Prior to Abbvie, Dr. Iyer was at Genentech for 11 years during which she participated in and led preclinical and clinical teams in immunology and oncology, resulting in key milestones for several programs. She began her R&D career at Sangstat Medical Corp with over 9 years in discovery and early research. She earned her Ph.D. from University of California at Davis, is a co-author on over 40 publications, has presented at numerous national and international forums and is a co-inventor on 5 patents.

Lixia-Wang (1)

Lixia Wang

Senior Vice President, Biometrics, Health Economics and
outcome Research, CTI BioPharma

Lixia Wang is Senior Vice President of CTI Biopharma Corp. She is responsible for managing Biometrics, Health Economic and Outcome Research in supporting drug and commercialized. With 24 years’ experience working cross big pharma, and biotech companies, Lixia has increasing responsibilities held multiple leadership positions and successfully supported many products worldwide registrations and reimbursements. Lixia is passionate to use innovation to bring technology, data science to expedite and improve drug . Lixia received his Ph.D. in Biostatistics from School of Public Health, University of South Carolina, had Master in Applied Statistics and Bachelor of Electronic and Computer Engineering.

Jason-Christiansen-270×260

Jason Christiansen

Vice President, Diagnostics, Ignyta

Elias-Kouchakji

Elias Kouchakji

Vice President, Clinical Development, Drug Safety,
and Pharmacovigilance, FibroGen

john Quackenbush-1

John Quackenbush
Professor of Computational Biology and Bioinformatics
Harvard T.H. Chan School of Public Health

ramon

Ramon Monhalal
Chief Medical Officer and Executive Vice President

BeyondSpring Pharmaceuticals

alok

Alok Bhushan

Chair of the Department of Pharmaceutical Sciences

Philadelphia University + Thomas Jefferson University

Siva-Narayanan

Siva Narayanan

Vice President and Global Head, Market Access, PTC Therapeutics Inc